Holen Sie sich die Stockscreener-App
4.03
6.33%
0.24
Vorhandelsmarkt:
4.01
-0.02
-0.50%
Lantern Pharma Inc Aktie (LTRN) Neueste Nachrichten
What drives Lantern Pharma Inc. stock priceFree Stock Market Forecast Reports - Autocar Professional
What analysts say about Lantern Pharma Inc. stockTremendous gains - jammulinksnews.com
Is Lantern Pharma Inc. a good long term investmentTriple-digit returns - jammulinksnews.com
Lantern Pharma Inc. Stock Analysis and ForecastBreakthrough capital growth - jammulinksnews.com
Lantern Pharma (NASDAQ: LTRN) Secures EU Patent For AI-Designed Cancer Drug LP-284 - Barchart.com
Lantern Pharma (LTRN) Secures EU Patent for Cancer Drug LP-284 - GuruFocus
Lantern Pharma secures EU patent for AI-driven cancer drug LP-284 - MSN
Lantern Pharma Secures EU Patent Allowance for LP-284, Bolstering Global IP Position for AI-Developed Cancer Therapy - BioSpace
Lantern Pharma (LTRN) Gains Patent Approval for Key Drug in Euro - GuruFocus
Lantern Pharma Unveils AI Module for Predicting Cancer Treatment Efficacy - AInvest
Lantern Pharma (NASDAQ: LTRN) Launches AI Module to Accelerate Development of Targeted Cancer Combination Therapies - The Globe and Mail
IBN Initiates Coverage of Lantern Pharma Inc. - GlobeNewswire
Lantern Pharma Initiates Coverage with IBN, Aims to Revolutionize Oncology Drug Development - AInvest
Why Lantern Pharma Inc. stock attracts strong analyst attentionFree Stock Movement Tracking - Newser
How Lantern Pharma Inc. stock performs during market volatilityInvestor Friendly Risk Reward - Newser
Lantern Pharma Inc. Unveils AI-Powered Module to Predict Activity and Efficacy of Combination Regimens in Clinical Cancer Treatment - MarketScreener
Lantern Pharma launches AI module to predict cancer treatment combos - Investing.com India
Lantern Pharma (LTRN) Launches AI Module for Cancer Treatment Ad - GuruFocus
Lantern Pharma launches AI module to predict cancer treatment combos By Investing.com - Investing.com South Africa
Lantern Pharma Unveils Groundbreaking AI-Powered Module to Predict Activity and Efficacy of Combination Regimens in Clinical Cancer Treatment - Business Wire
What makes Lantern Pharma Inc. stock price move sharplyFree Access to Community - Newser
LTRN Stock Price and Chart — NASDAQ:LTRN - TradingView
Lantern Pharma Enters ATM Sales Agreement with ThinkEquity - TipRanks
Why Lantern Pharma (NASDAQ: LTRN) Is ‘One to Watch’ - The Globe and Mail
Why Lantern Pharma (NASDAQ: LTRN) Is ‘One To Watch’ - Barchart.com
Lantern Pharma Inc. Harnesses AI to Revolutionize Oncology Drug Development - citybuzz -
Lantern Pharma’s (NASDAQ: LTRN) AI-Powered Platform Delivers Promising and Durable Results in Lung Cancer Trial - Barchart.com
Lantern Pharma (NASDAQ: LTRN) Reports Complete Response in Advanced NSCLC Patient in HARMONIC(TM) Trial - The Globe and Mail
Lantern Pharma Inc. Reports Complete Response in Advanced NSCLC Patient in HARMONIC(TM) Trial - citybuzz -
Lung Cancer Patient in Lantern Pharma's Harmonic Trial Shows Durable Complete Response in Target Cancer Lesions with Survival Continuing for Nearly Two Years | LTRN Stock News - GuruFocus
Lung Cancer Patient In Lantern Pharma's Harmonic Trial Shows Durable Complete Response In Target Cancer Lesions With Survival Continuing For Nearly Two Years - MarketScreener
Lung Cancer Patient in Lantern Pharma’s Harmonic Trial Shows Durable Complete Response in Target Cancer Lesions with Survival Continuing for Nearly Two Years - Yahoo Finance
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):